StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Aesthetics Portfolio by Quarter

Aesthetics Portfolio — International operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Aesthetics Portfolio: 5.0% in Q2 2026, up 13.3 pts from a year earlier.

Latest, Q2 2026
5.0%
Period ended Jun 30, 2026
Change on a year earlier
+13.3 pts
-8.3% in Q2 2025
History
24 quarters
Since Q2 2020
Sources
24
Documents cited below

Where the Q2 2026 figure comes from

“|| Aesthetics | 761 | 521 | 1,282 | (4.4) | 8.1 | 0.3 | 5.0 | (0.9)”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAesthetics Portfolio — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20265.0%+13.3 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 2026-1.5%-3.1 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20252.5%+5.7 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025-0.6%+1.0 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-8.3%-8.7 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 20251.6%+7.1 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024-3.2%-12.2 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024-1.6%+8.1 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20240.4%-18.9 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-5.5%-13.3 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 20239.0%+12.4 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-9.7%-47.1 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 202319.3%+17.2 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20237.8%-25.7 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-3.4%-29.2 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 202237.4%+18.5 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Aesthetics Portfolio (%), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-aesth-intl-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.